CA2396165A1 - Airway alkalinization as therapy for airway diseases - Google Patents

Airway alkalinization as therapy for airway diseases Download PDF

Info

Publication number
CA2396165A1
CA2396165A1 CA002396165A CA2396165A CA2396165A1 CA 2396165 A1 CA2396165 A1 CA 2396165A1 CA 002396165 A CA002396165 A CA 002396165A CA 2396165 A CA2396165 A CA 2396165A CA 2396165 A1 CA2396165 A1 CA 2396165A1
Authority
CA
Canada
Prior art keywords
composition
composition comprises
group
compound
airways
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002396165A
Other languages
French (fr)
Other versions
CA2396165C (en
Inventor
John F. Hunt
Benjamin M. Gaston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2396165A1 publication Critical patent/CA2396165A1/en
Application granted granted Critical
Publication of CA2396165C publication Critical patent/CA2396165C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to a method of treating asthma by raising the pH
of the airways of an individual. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution or alternatively, the effect can be mediated by enhancing the activity of glutaminase.

Claims (41)

1. A method for alleviating the symptoms associated with an asthma attack, said method comprising the step of contacting the airways of an asthmatic patient with a composition comprising an agent selected from the group consisting of albuterol, levalbuterol HC1, ipratroprium bromide and budesonide in a pharmaceutically acceptable basic solution.
2. The method of claim 1 wherein the pH of the basic solution ranges from about 7.4 to about 9.5.
3. A kit for treating asthma, said kit comprising a conventional agent selected from the group consisting of albuterol, levalbuterol HC1, ipratroprium bromide and budesonide; and a buffered diluent having a pH greater than 7.4.
4. The kit of claim 3 further comprising glutamine.
5. The kit of claim3 wherein the pH of the buffered diluent ranges from about 7.5 to about 9Ø
6. A method for enhancing the therapeutic efficacy of conventional asthmatic agents, said method comprising contacting the airways of a patient with a composition that reduces the proton/hydronium concentration in said airways either simultaneously or prior to administering the conventional asthmatic agent.
7. The method of claim 6 wherein the conventional asthmatic agent is selected from the group consisting of albuterol, levalbuterol HC1, and ipratroprium bromide.
8. The method of claim 7 wherein said composition comprises a corticosteroid.
9. The method of claim 8 wherein said corticosteroid is selected from the group consisting of hydrocortisone or dexamethasone and budesonide.
10. The method of claim 7 wherein said composition comprises an inhibitor of V ATP'ase or a stimulant of glutaminase.
11. The method of claim 7 wherein said composition comprises a basic solution.
12. The method of claim 7 wherein said composition comprises glutamine.
13. A method of treating asthma, said method comprising the step of administering to a patient a compound that inhibits aldehyde dehydrogenase.
14. The method of claim 13 wherein the aldehyde dehydrogenase inhibitor is disulfiram.
15. The method of claim 14 wherein the compound is administered by nebulization.
16. The method of claim 14 wherein the compound is administered systemically.
17. A method of treating asthma, said method comprising the step of administering to a patient an antifungal agent.
18. The method of claim 17 wherein the antifungal agent is fluconazole or disulfiram.
19. The method of claim 18 wherein the compound is administered by nebulization.
20. The method of claim 18 wherein the compound is administered systemically.
21. A method of treating asthma said method comprising the step of administering to a patient a compound selected from the group consisting of CuCl, Cu/Zn SOD, glutathione peroxidase, glutathione-dependent formaldehyde dehydrogenase or gamma glutamyl transpeptidase.
22. The method of claim 21 wherein the compound is administered by nebulization.
23. The method of claim 21 wherein the compound is administered systemically.
24. A composition comprising a conventional agent selected from the group consisting of albuterol, levalbuterol HCl, ipratroprium bromide and budesonide; and glutamine.
25. The composition of claim 24 further comprising a buffer having a pH
greater than 7.4.
26. The composition of claim 24 further comprising a compound selected from the group consisting of CuCl, Cu/Zn SOD, glutathione peroxidase, glutathione-dependent formaldehyde dehydrogenase or gamma glutamyl transpeptidase.
27. The composition of claim 24 further comprising a corticosteroid.
28. A method for treating asthma prophylactically, said method comprising the step of scrubbing protons present in the air through the use of environmental filters.
29. A method for treating asthma, said method comprising the step of administering a nebulized formulation comprising an antibody to gamma interferon.
30. The method of claim 29 wherein the antibody in a monoclonal antibody.
31. A method for treating microbial infection of the airways of a patient, said method comprising the steps of administering a composition that lowers the pH
of the airways to a range of about 6.0 to about 6.9.
32. The method of claim 31 wherein the microbial infection is a gram negative or mycobacterial infection.
33. The method of claim 32 wherein the composition comprises a proton donor.
34. The method of claim 33 wherein the proton donor is selected from the group consisting of acetic acid, phosphoric acid and hydrochloric acid.
35. The method of claim 32 wherein the composition comprises an S-nitrosothiols.
36. The method of claim 32 wherein the composition comprises Diazo-5-oxo-L-norleucine.
37. A method for treating a viral infection of the airways of a patient, said method comprising the steps of administering a composition that lowers the pH
of the airways to a range of about 6.0 to about 6.9.
38. The method of claim 37 wherein the composition comprises a proton donor.
39. The method of claim 38 wherein the proton donor is selected from the group consisting of acetic acid, phosphoric acid and hydrochloric acid.
40. The method of claim 37 wherein the composition comprises an S-nitrosothiols.
41. The method of claim 37 wherein the composition comprises Diazo-5-oxo-L-norleucine.
CA2396165A 2000-01-14 2001-01-12 Airway alkalinization as therapy for airway diseases Expired - Fee Related CA2396165C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17638800P 2000-01-14 2000-01-14
US60/176,388 2000-01-14
PCT/US2001/001062 WO2001051046A1 (en) 2000-01-14 2001-01-12 Airway alkalinization as therapy for airway diseases

Publications (2)

Publication Number Publication Date
CA2396165A1 true CA2396165A1 (en) 2001-07-19
CA2396165C CA2396165C (en) 2011-01-04

Family

ID=22644157

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2396165A Expired - Fee Related CA2396165C (en) 2000-01-14 2001-01-12 Airway alkalinization as therapy for airway diseases

Country Status (4)

Country Link
US (5) US6930125B2 (en)
AU (1) AU2001232787A1 (en)
CA (1) CA2396165C (en)
WO (1) WO2001051046A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7347825B2 (en) * 2001-04-17 2008-03-25 University Of Virginia Patent Foundation Device and method for assessing asthma and other diseases
DE50205128D1 (en) * 2001-07-16 2006-01-05 Greenhills Biotechnology Res D USE OF AN ANTIVIRAL COMPOUND CLASS (DITHIOCARBAMATE COMPOUNDS) FOR THE PREPARATION OF A MEANS FOR TREATMENT OR TREATMENT PREVENT VIRUS INFECTION IN THE RESPIRATORY TRACT
US7101341B2 (en) * 2003-04-15 2006-09-05 Ross Tsukashima Respiratory monitoring, diagnostic and therapeutic system
US7166201B2 (en) 2003-12-01 2007-01-23 Sierra Medical Technology Self-condensing pH sensor
CA2633099C (en) * 2005-12-21 2015-04-21 Uti Limited Partnership Treatment of respiratory diseases
WO2008137446A1 (en) * 2007-05-03 2008-11-13 Trustees Of Boston University Methods and compositions for the treatment of respiratory disease
US8911711B2 (en) * 2008-09-30 2014-12-16 The Invention Science Fund I, Llc Method, device, and system to control pH in pulmonary tissue of a subject
EP2477642A4 (en) * 2009-09-17 2013-03-13 Mutual Pharmaceutical Co Method of treating asthma with antiviral agents
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US11324774B2 (en) * 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
JP2020040924A (en) * 2018-09-13 2020-03-19 学校法人慶應義塾 Group 2 innate lymphoid cell (ilc2) activity inhibitor containing disulfiram
US11638722B2 (en) 2020-03-25 2023-05-02 Therapeutica Borealis Oy C/O Avance Attorneys Ltd. Medicine for Covid-19 and treatment
US11278602B2 (en) 2020-03-25 2022-03-22 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
US11007187B1 (en) * 2020-03-25 2021-05-18 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
WO2021207155A1 (en) * 2020-04-06 2021-10-14 The Trustees Of Indiana University Airway epithelial alkaline therapy to treat viral respiratory infection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69008454T2 (en) 1989-08-07 1994-08-25 Takeda Chemical Industries Ltd Nitrolsothiol derivatives, their production and use.
US5362755A (en) * 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US6136346A (en) 1995-04-14 2000-10-24 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
CN1108799C (en) 1996-06-25 2003-05-21 塞弗朗公司 Use of K-252A derivative for treatment of peripheral or central nerve disorders, and cytokine overproduction
US5906811A (en) 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US5906611A (en) * 1997-07-28 1999-05-25 Dodick; Jack Murray Surgical instrument with laser target
KR20060066753A (en) 1997-10-22 2006-06-16 젠스 포니카우 Use of antifungal agents for the topical treatment of fungus-induced mucositis
EP1333823B1 (en) * 2000-10-16 2010-03-31 Duke University Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis

Also Published As

Publication number Publication date
CA2396165C (en) 2011-01-04
US6930125B2 (en) 2005-08-16
AU2001232787A1 (en) 2001-07-24
US20070134166A1 (en) 2007-06-14
US20050222103A1 (en) 2005-10-06
US20070128126A1 (en) 2007-06-07
US7888385B2 (en) 2011-02-15
US20090054384A1 (en) 2009-02-26
WO2001051046A1 (en) 2001-07-19
US20030013695A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
CA2396165A1 (en) Airway alkalinization as therapy for airway diseases
ES2309503T3 (en) MEDICATION THAT INCLUDES A LONG-TERM BETA 2 AGONIST, VERY POWERFUL, IN COMBINATION WITH OTHER ACTIVE INGREDIENTS.
AU2005316687B2 (en) Compositions and methods for pulmonary conditions
JP2004525903A5 (en)
CA2540174A1 (en) Aerosol formulation for inhalation, containing an anticholinergic agent
JP6234899B2 (en) Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
CY1108776T1 (en) PREPARATION OF AIR PUMP FOR INHIBITION CONTAINING ANTI-CLINICAL
JP2003504368A5 (en)
JP2005505569A5 (en)
NZ555247A (en) Therapeutic compositions for intranasal administration of ketorolac
JP2006506345A5 (en)
AU2002211222A1 (en) Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis
US20100202979A1 (en) Compositions and methods for treatment of pulmonary diseases and conditions
WO2014158119A1 (en) Aqueous solution composition containing ipratropium and oxymetazoline
JPH02196716A (en) Pharmaceutical solution
JP4459303B2 (en) Method of treating disease in mammals resulting from inflammatory reaction and composition thereof
US20160136089A1 (en) Unit dose formulations of ketorolac for intranasal administration
US20090124632A1 (en) Methods and kits related to the topical administration of quinolone antibiotics°
US20020151562A1 (en) Compositions and methods for treating allergic fungal sinusitis
JPH10130148A (en) Composition for nebulizer
US20200108030A1 (en) Compositions of albuterol and hypertonic saline and uses thereof
CA2524074C (en) Oral composition to reduce cold symptoms and duration of same
US20070185205A1 (en) Airway Alkalinization as Therapy for Airway Diseases
Boothe Plugs, bugs and drugs: treating the respiratory tract.
Schuh EVIDENCE BASED MANAGEMENT OF SEVERE ASTHMA IN THE EMERGENCY DEPARTMENT

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160112